{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:22:56Z","timestamp":1788841376610,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901229"],"award-info":[{"award-number":["81901229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106850","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T02:55:23Z","timestamp":1762829723000},"page":"106850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Risk of hepatitis B and tuberculosis reactivation in patients with neuromyelitis optica spectrum disorder undergoing B cell depletion therapy"],"prefix":"10.1016","volume":"104","author":[{"given":"Xi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1932-3737","authenticated-orcid":false,"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106850_bib0001","unstructured":"Global hepatitis report 2024: action for access in low- and middle-income countries. Accessed October 10, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"key":"10.1016\/j.msard.2025.106850_bib0002","unstructured":"Global tuberculosis report 2023. Accessed October 10, 2025. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2023."},{"issue":"8","key":"10.1016\/j.msard.2025.106850_bib0003","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/hepr.13504","article-title":"Japan society of hepatology guidelines for the management of Hepatitis B virus infection: 2019 update","volume":"50","year":"2020","journal-title":"Hepatol. Res."},{"issue":"6","key":"10.1016\/j.msard.2025.106850_bib0004","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s00415-022-11009-x","article-title":"Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study","volume":"269","author":"Buonomo","year":"2022","journal-title":"J. Neurol."},{"issue":"0","key":"10.1016\/j.msard.2025.106850_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor- (TNF-) targeted biologics and recently licensed TNF- inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J. Rheumatol. Suppl."},{"issue":"2","key":"10.1016\/j.msard.2025.106850_bib0006","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2016.02.1240","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review","volume":"76","author":"Caplan","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.msard.2025.106850_bib0007","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106850_bib0008","doi-asserted-by":"crossref","first-page":"jiw606","DOI":"10.1093\/infdis\/jiw606","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment","author":"Chen","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.msard.2025.106850_bib0009","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/1756-185X.13582","article-title":"Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation","volume":"22","author":"Chen","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.msard.2025.106850_bib0010","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kes365","article-title":"The effects of rituximab therapy on released interferon- levels in the QuantiFERON assay among RA patients with different status of mycobacterium tuberculosis infection","volume":"52","author":"Chen","year":"2013","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.msard.2025.106850_bib0011","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3138\/canlivj.2018-0008","article-title":"Management of Hepatitis B Virus Infection: 2018 guidelines from the Canadian association for the study of liver disease and association of medical microbiology and infectious disease Canada","volume":"1","author":"Coffin","year":"2018","journal-title":"CanLivJ"},{"issue":"6","key":"10.1016\/j.msard.2025.106850_bib0012","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/09612033241239504","article-title":"Global tuberculosis disease and infection in systemic lupus erythematosus patients: a systematic review and meta-analysis","volume":"33","author":"Darmawan","year":"2024","journal-title":"Lupus."},{"key":"10.1016\/j.msard.2025.106850_bib0013","unstructured":"Elkourashy SA, Benkhadra M, Shafei L, Abujarir S, Ghasoub R. Disseminated tuberculosis after Polatuzumab-Vedotin based chemoimmunotherapy in a patient with Burkitt\u2019s lymphoma."},{"issue":"6","key":"10.1016\/j.msard.2025.106850_bib0014","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"issue":"2","key":"10.1016\/j.msard.2025.106850_bib0015","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1002\/iid3.780","article-title":"Risk of hepatitis B reactivation in HBsAg\u2212\/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: a meta-analysis","volume":"11","author":"Hong","year":"2023","journal-title":"Immun. Inflam Dis."},{"issue":"3","key":"10.1016\/j.msard.2025.106850_bib0016","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jvh.12305","article-title":"Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American association for the study of liver diseases","volume":"22","author":"Hwang","year":"2015","journal-title":"J. Viral. Hepat."},{"issue":"31","key":"10.1016\/j.msard.2025.106850_bib0017","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.msard.2025.106850_bib0018","doi-asserted-by":"crossref","unstructured":"Kim KH. Latent tuberculosis infection in Korean patients with multiple sclerosis and neuromyelitis optica spectrum disorder. Mult. Scler. Relat. Disord.. Published online 2024.","DOI":"10.1016\/j.msard.2023.105145"},{"issue":"10","key":"10.1016\/j.msard.2025.106850_bib0019","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00277-011-1241-0","article-title":"Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative\/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis","volume":"90","author":"Koo","year":"2011","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.msard.2025.106850_bib0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106850_bib0021","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.msard.2025.106850_bib0022","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/asheducation-2014.1.576","article-title":"Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy","volume":"2014","author":"Kusumoto","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.msard.2025.106850_bib0023","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","author":"Lau","year":"2021","journal-title":"Hepatol. Int."},{"issue":"6","key":"10.1016\/j.msard.2025.106850_bib0024","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.msard.2025.106850_bib0025","doi-asserted-by":"crossref","unstructured":"Mallet V. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations. 5th European Conference on Infections in Leukaemia (ECIL-5). 2016;16.","DOI":"10.1016\/S1473-3099(16)00118-3"},{"issue":"1","key":"10.1016\/j.msard.2025.106850_bib0026","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00415-023-11973-y","article-title":"Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study","volume":"271","author":"Marzo","year":"2024","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106850_bib0027","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.24875\/RIC.19002982","article-title":"Infectious complications as a predictor of mortality in patients with non-hodgkin lymphoma receiving Rituximab- containing chemotherapy","volume":"71","author":"Meza-Meneses","year":"2019","journal-title":"RIC"},{"key":"10.1016\/j.msard.2025.106850_bib0028","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study group for infections in compromised hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"issue":"3","key":"10.1016\/j.msard.2025.106850_bib0029","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458520952311","article-title":"The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement","volume":"27","author":"Moiola","year":"2021","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2025.106850_bib0030","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders \u2014 From mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106850_bib0031","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s13311-022-01206-x","article-title":"Monoclonal antibody therapies beyond complement for NMOSD and MOGAD","volume":"19","author":"Redenbaugh","year":"2022","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2025.106850_bib0032","unstructured":"Sarmati L. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of Hepatitis B virus reactivation in patients with haematological malignancies and patients who underwent haematological stem cell transplantation \u2013 a position paper."},{"issue":"33","key":"10.1016\/j.msard.2025.106850_bib0033","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous Hepatitis B virus exposure undergoing Rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.msard.2025.106850_bib0034","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28549","article-title":"HBsAg (\u2212)\/HBsAb (\u2212)\/HBeAg (\u2212)\/HBeAb (+)\/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy","volume":"95","author":"Shui","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2025.106850_bib0035","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1159\/000530711","article-title":"Miliary tuberculosis during R-MPV therapy in an elderly patient with primary Central nerve system lymphoma: a case report","author":"Take","year":"2023","journal-title":"Case Rep. Oncol."},{"issue":"11","key":"10.1016\/j.msard.2025.106850_bib0036","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1080\/14712598.2022.2145879","article-title":"Transitioning immunotherapy in neuromyelitis optica spectrum disorder \u2013 when and how to switch","volume":"22","author":"Vishnevetsky","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.msard.2025.106850_bib0037","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Published online 2015.","DOI":"10.1093\/med\/9780199341016.003.0023"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:33:10Z","timestamp":1784345590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S2211034825005929"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106850","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of hepatitis B and tuberculosis reactivation in patients with neuromyelitis optica spectrum disorder undergoing B cell depletion therapy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106850"}}